Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma Clinical Trials in Philadelphia, Pennsylvania

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma